ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings is a strong and established player in the orthopedic market, with a leading share in the US, Europe, and Japan. The recent acquisitions and spin-offs have streamlined its focus on large joints, extremities, trauma and surgical products, highlighting its strategic transformation goals. While 1Q26 revenue and margins beat expectations, several crosscurrents made for a more complicated quarter and weaker rest-of-year optics. However, with improving top line and a focus on cost pressures, there could be potential for upside.

Zimmer Biomet Holdings is facing several challenges that negatively impact their target price, including intense competition, inconsistent quarterly performance, uncertainty around product innovation success, and potential instability in the US macroeconomic environment. Despite a slight beat in 1Q26 results, with sales of $2.09 billion and EPS of $2.09, the company's knees underperformed domestically and internationally, while their hip portfolio showed steady growth. The recent acquisition of Paragon 28 seems promising, but ZBH still faces executional hurdles and may not meet their 2026 LRP goals, resulting in multiple contraction and lowered price target to $105.